Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against .
Kessler Topaz Meltzer & Check LLPJuly 8, 2021 GMT
RADNOR, Pa., July 07, 2021 (GLOBE NEWSWIRE) The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed in the United States District Court for the Western District of Washington against Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira”) on behalf of those who purchased or acquired Athira common stock:
a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Athira’s September 2020 initial public offering; and/or b) between September 18, 2020 and June 17, 2021, inclusive (the “Class Period”).
no later than August 20, 2021
, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Home Point Capital Inc.
Home Point Capital operates as a residential mortgage originator and service provider
On January 29, 2021, Home Point Capital launched its IPO, issuing 7.25 million shares of Home Point Capital s common stock to the public at the offering price of $13.00 per share. Net proceeds of the offering were approximately $88 million.
According to the filed Complaint, the Company made false and misleading statements to the market. Home Point s plan to aggressively expand its broker partners would in turn dramatically increase its expenses. The mortgage industry anticipated shrinking gain-on-sale margins due to rising interest rates, resulting in increased competitive pressures on the Company. The Company overstated its business and growth prospects. Based on th
Home / Top News / SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Technologies, Inc. f/k/a ATI Intermediate Holdings, LLC of Class Action Lawsuit and Upcoming Deadline – ARRY
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Technologies, Inc. f/k/a ATI Intermediate Holdings, LLC of Class Action Lawsuit and Upcoming Deadline – ARRY
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Array Technologies, Inc. f/k/a ATI Intermediate Holdings, LLC (“Array” or the “Company”) (NASDAQ: ARRY) and certain of its officers and directors. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-05658, is on behalf of:
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp., of Class Action Lawsuit and Upcoming Deadline – DKNG
07/07/2021 | 11:45pm EDT
Send by mail :
Message :
Required fields
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. (“DEAC”, “DraftKings”, or the “Company”) (NASDAQ: DKNG) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-05739, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired DraftKings securities between December 23, 2019 and June 15, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal secu
Toll free (844) 887-9500
Athira is a late-stage clinical biopharmaceutical company that focuses on developing small molecules to restore neuronal health and stop neurodegeneration.
The complaints allege that in the Registration Statement and/or throughout the Class Period the defendants made materially false and misleading statements and omitted to state that: (1) Athira s president and Chief Executive Officer, Dr. Leen Kawas, had published research papers containing improperly altered images while she was a graduate student; (2) this purported research was foundational to Athira s efforts to develop treatments for Alzheimer s because it laid the biological groundwork that Athira was using in its approach to treating Alzheimer s; (3) as a result, Athira s intellectual property and product development for the treatment of Alzheimer s was based on invalid research; and (4) as a result of the foregoing, the defendants positive statements about Athira s business, operations, a